Multiplex fluorescence immunohistochemical kit and evaluation system for evaluating immune microenvironment of skin squamous cell carcinoma

By using multiplex fluorescent immunohistochemistry kits and techniques, the challenge of assessing the immune microenvironment in cutaneous squamous cell carcinoma has been solved, enabling precise assessment of the tumor microenvironment and comprehensive study of cell relationship structures, thus providing new treatment strategies.

CN118962140APending Publication Date: 2024-11-15SHANGHAI KUARAN KAILANG MEDICAL LAB CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411058612.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively assess the cellular relationships within the immune microenvironment of squamous cell carcinoma of the skin, and cannot comprehensively study cellular composition and intercellular interactions, thus affecting the formulation of treatment strategies.

Method used

A multiplex fluorescent immunohistochemistry kit containing monoclonal antibodies against CD8, CD20, CD23, CD45, PANCK, and PDL1, along with corresponding fluorescent dyes, was used to simultaneously detect multiple target sites in squamous cell carcinoma tissue of the skin, enabling precise assessment of both tumor and stromal regions.

Benefits of technology

It enables precise assessment of the tumor microenvironment of squamous cell carcinoma of the skin, allowing for the simultaneous detection of multiple targets, study of cellular composition and intercellular interactions, and helps in screening patients who will benefit clinically, providing new treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962140A_ABST
    Figure CN118962140A_ABST
Patent Text Reader

Abstract

The invention discloses a multiple fluorescence immunohistochemical kit for evaluating a skin squamous cell carcinoma immune microenvironment and an evaluation system. The multiple fluorescence immunohistochemical kit comprises a monoclonal antibody group serving as a primary antibody and a fluorescent dye group, the monoclonal antibody group comprises a CD8 monoclonal antibody, a CD20 monoclonal antibody, a CD23 monoclonal antibody, a CD45 monoclonal antibody, a PANCK monoclonal antibody and a PDL1 monoclonal antibody; the fluorescent dye group comprises six different fluorescent dyes which are respectively in one-to-one correspondence with the monoclonal antibodies. According to the invention, the exploration of the mIHC technology in skin squamous cell carcinoma immune microenvironment evaluation is realized through the design of immune biomarkers and the design of a corresponding multi-fluorescence immunohistochemical kit, and the technology can be utilized to accurately screen clinical benefit people.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biological detection technology, and in particular to a multiplex fluorescent immunohistochemistry kit and an evaluation system for evaluating the immune microenvironment of skin squamous cell carcinoma. Background Art

[0002] Primary cutaneous squamous cell carcinoma (cSCC) is the second most common human cancer, with an incidence of approximately 1.8 million cases per year in the United States. Primary squamous cell carcinoma is usually curable with surgery, however, in some cases, cSCC eventually leads to lymph node metastasis and disease-specific death, with cSCC causing up to 15,000 deaths per year in the United States. Non-surgical options for treating locally advanced or metastatic cSCC are largely ineffective. In recent years, immunotherapy has shown some effectiveness in cSCC, and with the advent of checkpoint inhibitor immunotherapy (including cemiplizumab and pembrolizumab), response rates have climbed to 50%, a huge improvement over previously used chemotherapy drugs.

[0003] The tumor microenvironment is a complex system composed of cells and molecules that will provide the necessary conditions for the development and progression of tumors. Cells residing in the tumor microenvironment acquire specific phenotypes and have specific functions that promote tumors. In fact, tumor progression is a combination of tumor cell characteristics and their interaction with the tumor microenvironment. This dynamic network will allow tumor cells to grow, migrate and invade tissues. In recent years, the tumor microenvironment plays a key role in the progression of cancers, including head and neck squamous cell carcinoma (HNSCC). Immune cells, stromal cells and extracellular components are closely related to tumor development, forming a complex regulatory network that affects tumor growth and metastasis.

[0004] The tumor immune microenvironment is composed of cytotoxic T lymphocytes with anti-tumor immune effects, natural killer cells, myeloid-derived suppressor cells (MDSC) that produce immunosuppressive effects, regulatory T cells, and tumor-associated macrophages. A large number of CTL infiltrations in HNSCC tissues are associated with the overall survival of patients, and the lymphocytes infiltrating the tumor are mostly CD8+T lymphocytes. Studies have confirmed that the higher the infiltration degree of CD8+T lymphocytes, the longer the survival of patients. Therefore, a large number of CD8+T lymphocyte infiltrations can be used as a favorable prognostic factor for HNSCC. Studies have found that small molecule inhibitors PTC209+anti-PD1 antibodies targeting BMI can increase the infiltration of GZMB+ and CD8+T cells in tumors by inducing the expression of type I IFN chemokines (CCL5, CXCL9, CXCL10, and CXCL11), effectively inhibiting the progression and recurrence of HNSCC. In addition, PD-L1 regulates the activity of T cells, activates antigen-specific activation and circulation, and is related to the drug resistance and poor clinical prognosis of patients. Justesen et al. analyzed the ratio of neutrophils and lymphocytes in the blood of patients with HPV+\HPV- squamous cell carcinoma of the oropharynx and their prognosis, and found that increased NLR was a risk factor for poor prognosis in patients with oropharyngeal squamous cell carcinoma, regardless of whether the patient was infected with HPV. The limitation of this study is that NLR is not a cancer-specific biomarker and may be affected by other diseases. In addition, some studies have suggested that elevated NLR may be caused by advanced malignant diseases and is related to tumor volume, lymph node stage, and number of metastases. Further trials are needed to include NLR in the prediction of treatment de-escalation, especially focusing on the problem of confounding comorbidities. In summary, the interaction of various factors in the tumor microenvironment promotes the occurrence, development, and metastasis of tumors. Therefore, understanding their biological characteristics and targeting their regulation can provide new strategies and directions for treating tumors.

[0005] mIHC technology can evaluate the density and cell population of inflammatory infiltration in skin tumors. In-depth analysis of tumor microculture may provide new insights into cancer treatment and identify new therapeutic targets. Therefore, it is necessary for technicians in this field to study the phenotype and function of Langerhans cells, dendritic cells, macrophages, myeloid-derived suppressor cells and T cells associated with squamous cell carcinoma, as well as squamous cell carcinoma-related lymphatic vessels and blood vessels; summarize the possible role of squamous cell carcinoma-related cytokines in progression and invasion, and verify the possible role of squamous cell carcinoma-related cytokines in progression and invasion by mIHC method, and discuss and evaluate the immune microenvironment of squamous cell carcinoma. Summary of the invention

[0006] The purpose of the present invention is to provide a multiplex fluorescent immunohistochemistry kit and an evaluation system for evaluating the immune microenvironment of skin squamous cell carcinoma in view of the deficiencies in the prior art.

[0007] To achieve the above object, the technical solution adopted by the present invention is:

[0008] The first aspect of the present invention provides a multiplex fluorescent immunohistochemistry kit for evaluating the immune microenvironment of skin squamous cell carcinoma, comprising a monoclonal antibody group as a primary antibody and a fluorescent dye group;

[0009] The monoclonal antibody group includes CD8 monoclonal antibody, CD20 monoclonal antibody, CD23 monoclonal antibody, CD45 monoclonal antibody, PANCK monoclonal antibody and PDL1 monoclonal antibody;

[0010] The fluorescent dye set includes six different fluorescent dyes, each corresponding to the monoclonal antibody.

[0011] Furthermore, the fluorescent dye is a TSA dye, including a 570nm fluorescent dye, a 480nm fluorescent dye, a 620nm fluorescent dye, a 690nm fluorescent dye, a 780nm fluorescent dye, and a 520nm fluorescent dye corresponding to CD8 monoclonal antibody, CD20 monoclonal antibody, CD23 monoclonal antibody, CD45 monoclonal antibody, PANCK monoclonal antibody, and PDL1 monoclonal antibody, respectively.

[0012] Furthermore, the fluorescent dye set also includes a signal amplification solution.

[0013] Furthermore, the preparation method of the primary antibody working solution is as follows: CD8 is diluted at 1:200, CD20 is diluted at 1:400, CD23 is diluted at 1:1000, CD45 is diluted at 1:600, PD-L1 is diluted at 1:500, and PANCK is diluted at 1:1000 to prepare a combined primary antibody working solution.

[0014] Furthermore, the multiplex fluorescent immunohistochemistry kit also includes antigen repair solution, non-specific protein blocking agent, secondary antibody, antibody diluent, buffer, nuclear staining agent, mounting medium, dewaxing agent, and hydrating agent.

[0015] Furthermore, the antigen repair solution is Tris-EDTA antigen repair solution, pH9.0, the dilution ratio of the Tris-EDTA antigen repair solution, pH9.0 stock solution is 1:50, and the pH is 9.0; the non-specific protein blocking agent includes bovine serum albumin; the secondary antibody is a secondary antigen solution matched with TSA dye; the buffer is 1×TBST buffer; the nuclear stain is a DAPI stock solution diluted with deionized water; the mounting medium is a water-soluble anti-fluorescence quenching mounting medium; the dewaxing agent includes xylene; the hydrating agent includes ethanol with a gradient concentration of 100%, 95%, and 75% by volume.

[0016] The second aspect of the present invention is to provide a skin squamous cell carcinoma immune microenvironment assessment system, comprising a multiplex fluorescent immunohistochemistry kit as described in any one of claims 1 to 6 and a pathological image acquisition and analysis system adapted thereto; a pathological image is obtained by performing multiplex fluorescent immunohistochemistry operations on biological samples; the pathological image acquisition and analysis system acquires an image of the pathological image and analyzes the image based on the following markers: CD8, CD20, CD23, CD45, PANCK and PDL1.

[0017] Furthermore, when the skin squamous cell carcinoma immune microenvironment assessment system is used for multiple fluorescent immunohistochemistry operations, after the specimen is dewaxed and hydrated, the antigen repair and staining round operation conditions of each antibody in the primary monoclonal antibody group are as follows:

[0018] In the first round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with CD45 primary antibody for 60 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 690 nm, rinsing with TBST 3 times for 3 min each;

[0019] In the second round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with CD8 primary antibody for 60 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 570 nm, rinsing with TBST 3 times for 3 min each;

[0020] In the third round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with PDL1 primary antibody for 30 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 520 nm, rinsing with TBST 3 times for 3 min each;

[0021] In the fourth round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with CD20 primary antibody for 30 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 480 nm, rinsing with TBST 3 times for 3 min each;

[0022] In the fifth round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with CD23 primary antibody for 60 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 620 nm, rinsing with TBST 3 times for 3 min each;

[0023] In the sixth round, Tris-EDTA antigen retrieval solution, pH 9.0, was used for antigen retrieval for 15 min, blocked for 10 min, incubated with PANCK primary antibody for 60 min, rinsed with TBST 3 times for 3 min each, incubated with HRP secondary antibody for 10 min, rinsed with TBST 3 times for 3 min each, stained with TSA at 780 nm, and rinsed with TBST 3 times for 3 min each.

[0024] Furthermore, the preparation method of TSA dye is as follows: dilute the fluorescent dye mother solution in 100ul signal amplification solution at a ratio of 1:100 and prepare it before use.

[0025] Furthermore, the biological sample is skin squamous cell carcinoma tissue.

[0026] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:

[0027] The present invention realizes the exploration of mIHC technology in the evaluation of the immune microenvironment of skin squamous cell carcinoma through the design of immune biomarkers and the corresponding multiple fluorescent immunohistochemistry kit, which helps to use this technology to accurately screen the clinical benefit population. The present invention solves the technical problem of evaluating the state of the cell relationship structure of different cell spatial positions in the tumor microenvironment of skin squamous cell carcinoma, and can simultaneously detect multiple target points on a single cell or tissue sample through the tumor area and the interstitial area, and comprehensively study the cell composition, cell function and cell-to-cell interaction. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Immunostaining results of different concentrations of CD8 antibody are shown; A, 1:200; B, 1:400; C, 1:600.

[0029] Figure 2 Immunostaining results of different concentrations of CD20 antibody are shown; A, 1:200; B, 1:400; C, 1:600.

[0030] Figure 3 Immunostaining results of different concentrations of CD23 antibody are shown; A, 1:1500; B, 1:1000; C, 1:500.

[0031] Figure 4 Immunostaining results of different concentrations of CD45 antibody are shown; A, 1:300; B, 1:600; C, 1:900.

[0032] Figure 5 Immunostaining results of different concentrations of PDL1 antibody are shown; A, 1:300; B, 1:500; C, 1:700.

[0033] Figure 6 Immunostaining results of different concentrations of PANCK antibody are shown; A, 1:1000; B, 1:1500; C, 1:2000.

[0034] Figure 7 The immunostaining results of different fluorescent dyes and staining rounds of CD8 antibodies in different panel schemes are shown; A, CD8-570 dye in panel 1, in the second round of repair; B, CD8-520 dye in panel 2, in the second round of repair.

[0035] Figure 8 The immunostaining results of different fluorescent dyes and staining rounds of CD20 antibody in different panel schemes are shown; A, CD20-480 dye in panel 1, repaired in the 4th round; B, CD20-620 dye in panel 2, repaired in the 4th round.

[0036] Fig. 9 The immunostaining results of different fluorescent dyes and staining rounds of CD23 antibodies in different panel schemes are shown; A, CD23-620 dye in panel 1, repaired in the 5th round; B, CD23-480 dye in panel 2, repaired in the 5th round.

[0037] Fig.10 The immunostaining results of different fluorescent dyes and staining rounds of CD45 antibody in different panel schemes are shown; A, CD45-690 dye in panel 1, repaired in the first round; B, CD45-690 dye in panel 2, repaired in the first round.

[0038] Fig.11 The immunostaining results of different fluorescent dyes and staining rounds of PDL1 antibody in different panel schemes are shown; A, PDL1-520 dye in panel 1, repaired in the 3rd round; B, PDL1-570 dye in panel 2, repaired in the 3rd round.

[0039] Fig.12The immunostaining results of different fluorescent dyes and staining rounds of PANCK antibody in different panel schemes are shown; A, panck-780 dye in panel 1, repaired in the 6th round; B, panck-780 dye in panel 2, repaired in the 6th round. DETAILED DESCRIPTION

[0040] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but is not intended to be limiting of the present invention. It should be noted that the embodiments and features in the embodiments of the present invention may be combined with each other without conflict.

[0041] 1. Detection markers

[0042] The present invention proposes six independent markers for mIHC slice preparation, namely, cytotoxic T cell marker CD8, mature B cell marker CD20, follicular dendritic cell marker CD23, leukocyte common antigen marker CD45, broad-spectrum keratin marker PANCK, and programmed cell death ligand marker PDL1.

[0043] II. Immune biomarker concentration and staining protocol

[0044] According to the preliminary experimental conditions, the optimal experimental concentrations and experimental conditions were selected for these six indicators, the best targets were reasonably matched according to the characteristics of each dye, and the staining rounds were designed. The six indicators were stained sequentially using multiple fluorescent immunohistochemistry technology.

[0045] Specifically, CD8 was diluted at 1:200, CD20 was diluted at 1:400, CD23 was diluted at 1:1000, CD45 was diluted at 1:600, PD-L1 was diluted at 1:500, and PANCK was diluted at 1:1000.

[0046] In terms of dyes, we first analyze the characteristics of each dye: 520 and 570 dyes have strong and stable binding to antibodies, 620 dye has moderate and stable binding to antibodies, 480 dye has autofluorescence problems, 690 dye has nonspecific staining problems, and 780 dye has relatively weak binding.

[0047] Through multiple experimental explorations, the fluorescent dyes compatible with each antibody are as follows: CD8-570nm fluorescent dye, CD20-480nm fluorescent dye, CD23-620nm fluorescent dye, CD45-690nm fluorescent dye, PANCK-780nm fluorescent dye, and PDL1-520nm fluorescent dye.

[0048] When performing multiple immunohistochemical analysis, the staining rounds were as follows: CD45-690nm fluorescent dye, CD8-570nm fluorescent dye, PDL1-520nm fluorescent dye, CD20-480nm fluorescent dye, CD23-620nm fluorescent dye, PANCK-780nm fluorescent dye.

[0049] Based on the above results, the specific technical solutions of the present invention are as follows:

[0050] The first aspect of the present invention provides a multiplex immunohistochemistry kit for evaluating the microenvironment of skin squamous cell carcinoma, comprising a monoclonal antibody group as a primary antibody and a fluorescent dye group;

[0051] The monoclonal antibody panel includes CD8 monoclonal antibody, CD20 monoclonal antibody, CD23 monoclonal antibody, CD45 monoclonal antibody, PANCK monoclonal antibody, and PDL1 monoclonal antibody;

[0052] The fluorescent dye set includes six different fluorescent dyes, each corresponding to the monoclonal antibody.

[0053] Specifically, the fluorescent dye is a TSA dye, including 570nm fluorescent dye, 480nm fluorescent dye, 620nm fluorescent dye, 690nm fluorescent dye, 780nm fluorescent dye, and 520nm fluorescent dye corresponding to CD8 monoclonal antibody, CD20 monoclonal antibody, CD23 monoclonal antibody, CD45 monoclonal antibody, PANCK monoclonal antibody, and PDL1 monoclonal antibody, respectively. In addition, the fluorescent dye group also includes a signal amplification solution for diluting the fluorescent dye mother solution to prepare a fluorescent dye working solution.

[0054] The preparation method of TSA dye is as follows: dilute the fluorescent dye mother solution in 100mL (100ul) signal amplification solution at a ratio of 1:100 and prepare it before use.

[0055] The preparation method of the primary antibody working solution is as follows: CD8 is diluted at 1:200, CD20 is diluted at 1:400, CD23 is diluted at 1:1000, CD45 is diluted at 1:600, PD-L1 is diluted at 1:500, and PANCK is diluted at 1:1000 to prepare a combined primary antibody working solution.

[0056] Preferably, the multiple immunohistochemistry kit for evaluating the microenvironment of skin squamous cell carcinoma provided by the present invention also includes antigen repair solution, nonspecific protein blocker, secondary antibody, antibody diluent, buffer, nuclear stain, mounting medium, dewaxing agent, and hydrating agent.

[0057] The specific composition of each reagent is as follows: antigen retrieval solution Tris-EDTA antigen retrieval solution, pH 9.0, the dilution ratio of the retrieval solution is 1:50, and the pH is 9.0; the non-specific protein blocking agent includes bovine serum albumin; the secondary antibody is the secondary antigen solution matched with TSA dye; the buffer is 1×TBST buffer; the nuclear stain is the DAPI stock solution diluted with deionized water; the mounting medium is a water-soluble anti-fluorescence quenching mounting medium; the dewaxing agent includes xylene; the hydrating agent includes ethanol with gradient concentrations of 100%, 95%, and 75% by volume.

[0058] When using this multiplex immunohistochemistry kit for multiplex immunoassay, the preparation steps of the slices include dewaxing and hydration, first antigen repair, serum blocking, primary antibody incubation, secondary antibody incubation, TSA dye incubation and staining, DAPI staining, and sealing. Because it contains multiple primary antibodies, it is necessary to repeat the antigen repair ~ TSA dye incubation and staining steps six times, and six rounds of six antibody binding staining are achieved. The specific conditions are shown in Table 1 below:

[0059] Table 1

[0060]

[0061]

[0062] In the second aspect of the present invention, a skin squamous cell carcinoma immune microenvironment assessment system is provided, including a multiple fluorescent immunohistochemistry kit and a pathological image acquisition and analysis system adapted thereto. The multiple fluorescent immunohistochemistry kit obtains pathological images by performing immunohistochemical operations (fluorescent immune signal capture) on biological samples; the pathological image acquisition and analysis system acquires images of the pathological images, and determines the maker in the tumor and analyzes each cell subpopulation on the same tissue section based on the following markers: CD8, CD20, CD23, CD45, PANCK, and PDL1.

[0063] The above biological sample is skin squamous cell carcinoma tissue.

[0064] Example 1

[0065] The reagents and raw materials used in this example are all commercially available or can be prepared according to literature methods. The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions such as those described in Sambrook et al. Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to conventional conditions, or according to the conditions recommended by the manufacturer. Unless otherwise specified, percentages and parts are calculated by volume.

[0066] 1. Detection markers

[0067] In the evaluation of multiple fluorescent immunohistochemistry technology and the exploration of immunohistochemistry technology in the microenvironment state of in situ cutaneous squamous cell carcinoma provided in this embodiment, the markers used include cytotoxic T cell marker CD8, mature B cell marker CD20, follicular dendritic cell marker CD23, leukocyte common antigen marker CD45, broad-spectrum keratin marker PANCK, and programmed cell death ligand marker PDL1.

[0068] II. Materials and Reagents of Multiplex Fluorescence Immunohistochemistry Kit

[0069] The reagents used in the multiplex fluorescent immunohistochemistry technique are as follows: antigen retrieval solution, nonspecific protein blocking agent, primary antibody, secondary antibody, antibody diluent, TSA dye, buffer, DAPI working solution, mounting medium, dewaxing agent, hydrating agent, ultrapure water, etc.

[0070] Among them, the antigen retrieval solution is Tris-EDTA antigen retrieval solution, pH 9.0;

[0071] Nonspecific protein blocking agents include bovine serum albumin;

[0072] The primary antibodies include CD8 monoclonal antibody, CD20 monoclonal antibody, CD23 monoclonal antibody, CD45 monoclonal antibody, PANCK monoclonal antibody and PDL1 monoclonal antibody;

[0073] Secondary antibodies included horseradish peroxidase-conjugated IgG antibodies;

[0074] The TSA dye includes a multi-target immunofluorescence staining kit, which includes a 570nm fluorescent dye, a 480nm fluorescent dye, a 620nm fluorescent dye, a 690nm fluorescent dye, a 780nm fluorescent dye, a 520nm fluorescent dye and a signal amplification solution;

[0075] Buffers included 1× TBST buffer;

[0076] DAPI working solution includes DAPI stock solution;

[0077] The mounting medium includes a water-soluble anti-fluorescence quenching mounting medium;

[0078] The dewaxing agent includes xylene; the hydrating agent includes ethanol with gradient concentrations of 100%, 95%, and 75% (volume fraction).

[0079] The preparation method of the above reagents is as follows:

[0080] a) Antigen retrieval solution

[0081] 20mL Tris-EDTA antigen retrieval solution, pH 9.0 stock solution is dissolved in 1000mL ultrapure water, the pH value of the solution is monitored with pH test paper, and the pH is adjusted to 9.0 (usually with hydrochloric acid) to obtain antigen retrieval solution;

[0082] b) Primary Antibody

[0083] Cell marker CD8, mature B cell marker CD20, follicular dendritic cell marker CD23, leukocyte common antigen marker CD45, broad-spectrum keratin marker PANCK and programmed cell death ligand marker PDL1. Antibodies were diluted to the corresponding multiples with antibody diluent according to the antibody instructions to obtain the primary antibody working solution. The specific dilution multiples are as follows: CD8 (1:200), CD20 (1:400), CD23 (1:1000), CD45 (1:600), PANCK (1:1000), PDL1 (1:500);

[0084] c) Secondary Antibody

[0085] Select the secondary antigen solution that comes with TSA dye and use it directly as the secondary antibody working solution;

[0086] d) TSA dye working solution

[0087] Take 1 mL of fluorescent dye stock solution (1:100) and dilute it in 100 mL of signal amplification solution. Prepare it before use.

[0088] d) 1× TBST buffer

[0089] Mix 50 mL of the 20-fold stock solution with 950 mL of sterile deionized water to prepare 1000 mL of 1× TBST buffer and bottle it for later use;

[0090] e) DAPI working solution: DAPI working solution was diluted 100 times in deionized water and prepared before use.

[0091] f) Xylene: use analytical grade stock solution;

[0092] g) Gradient concentrations of 100%, 95%, and 75% ethanol: 100% ethanol was directly used from 100 mL of the original anhydrous ethanol; 95% ethanol was prepared from 5 mL of sterile deionized water and 95 mL of anhydrous ethanol; 75% ethanol was prepared from 25 mL of sterile deionized water and 75 mL of anhydrous ethanol;

[0093] h) Deionized water sterilization: Prepare 1800 mL of deionized water and dispense into 6 bottles, with the liquid volume less than 2 / 3, 300 mL / bottle, mark the sterilization date, and sterilize at 0.15 MPa, 121°C for 30 minutes.

[0094] 3. Primary Antibody Concentration Screening

[0095] Different antibodies were tested in gradient concentrations, and the most suitable concentration was selected as the concentration for the multiple labeling experiment based on the fluorescence staining results, as follows:

[0096] CD8: Set three different gradients of primary antibody concentrations of 1:200, 1:400, and 1:600, and perform immunofluorescence staining. The results showed that at 1:600, the localization was clear, some areas were not expressed, and the expression was too weak ( Figure 1 C); 1:400, clear positioning, slightly weak expression ( Figure 1 B); 1:200, clear positioning, moderate expression intensity ( Figure 1 A).

[0097] CD20: Three different gradients of primary antibody concentrations were set at 1:200, 1:400, and 1:600, and immunofluorescence staining was performed respectively. The results showed that at 1:200, the localization was clear and the expression intensity was slightly weaker ( Figure 2 A); 1:400, clear positioning, moderate expression intensity ( Figure 2 B); 1:600, clear positioning, too strong expression intensity, easy to bleed into other channels in fluorescence experiments ( Figure 2 C);

[0098] CD23: Set three different gradients of primary antibody concentrations of 1:1500, 1:1000, and 1:500, and perform immunofluorescence staining respectively. The results show that at 1:500, the localization is clear, and the expression intensity is too strong, which is easy to bleed into other channels in the fluorescence experiment ( Figure 3 A); 1:1000, clear positioning, moderate expression intensity ( Figure 3 B); 1:1500, clear positioning, slightly weaker expression intensity ( Figure 3 C);

[0099] CD45: Set three different gradients of primary antibody concentrations of 1:300, 1:600, and 1:900, and perform immunofluorescence staining respectively. The results show that at 1:300, the localization is clear, and the expression intensity is too strong, which is easy to bleed into other channels in the fluorescence experiment ( Figure 4 A); 1:600, clear positioning, moderate expression intensity ( Figure 4 B); 1:900, clear positioning, slightly weaker expression intensity ( Figure 4 C);

[0100] PDL1: Set three different gradients of primary antibody concentrations of 1:300, 1:500, and 1:700, and perform immunofluorescence staining respectively. The results show that at 1:300, the localization is clear, and the expression intensity is too strong, which is easy to bleed into other channels in the fluorescence experiment ( Figure 5 A); 1:500, clear positioning, moderate expression intensity ( Figure 5 B); 1:700, clear positioning, slightly weaker expression intensity ( Figure 5 C);

[0101] PANCK: Set three different primary antibody concentrations of 1:1000, 1:1500, and 1:2000, and perform immunofluorescence staining respectively. The results showed that at 1:1000, the localization was clear and the expression intensity was moderate ( Figure 6 A); 1:1500, clear positioning, slightly weaker expression intensity ( Figure 6 B); 1:2000, no expression ( Figure 6 C).

[0102] Therefore, the most suitable antibody concentration can be screened for multi-label experiments. They are: CD8: 1:200, CD20: 1:400, CD231:1000, CD45: 1:600, PD-L1: 1:500, panck: 1:1000

[0103] IV. Multiplex fluorescent immunohistochemistry experimental steps

[0104] a) Dewaxing and hydration

[0105] The slides with specimens were placed in three portions of xylene in sequence, each for 5 minutes to complete dewaxing; then placed in two portions of 100% ethanol in sequence, each for 5 minutes; then placed in 95% ethanol for 3 minutes, and finally placed in 75% ethanol for 2 minutes, and washed with sterile deionized water 3 times, each for 1 minute, to complete hydration;

[0106] b) First antigen retrieval

[0107] Pour antigen repair solution into the repair box, boil it on high heat in a microwave oven (it takes about 3-4 minutes, the boiling time is subject to actual measurement), put in the glass slide to be repaired and cook on low heat for 15 minutes, take it out and cool it naturally to room temperature;

[0108] c) Serum blocking

[0109] The repaired slides were rinsed once with 1×TBST buffer and once with ultrapure water, excess water was shaken off, the tissue was circled with a histochemical pen, nonspecific protein blocking agent was added, and the slides were incubated at room temperature for 10 minutes with moisturizing (room temperature refers to 25°C, and moisturizing refers to maintaining appropriate humidity, which is understood in the conventional way, the same below);

[0110] d) Primary antibody incubation

[0111] Discard the blocking solution, add the primary antibody working solution diluted with antibody diluent, incubate at room temperature for 30-60 minutes (can be adjusted according to the specificity of the antibody), and rinse 3 times with 1×TBST buffer, 2 minutes each time;

[0112] e) Secondary antibody incubation

[0113] Discard the washing solution, add the secondary antibody working solution, incubate at room temperature for 10 minutes, and rinse 3 times with 1× TBST buffer, 2 minutes each time;

[0114] f) TSA incubation staining

[0115] Discard the washing solution, add the fluorescent dye working solution corresponding to the primary antibody in TSA dye, incubate at room temperature for 10 minutes, and rinse 3 times with 1× TBST buffer, 2 minutes each time;

[0116] g) Second antigen retrieval

[0117] Pour antigen repair solution into the repair cup, boil it on high heat in a microwave oven (the boiling time is subject to actual measurement), put in the incubated slides to be repaired and heat it on low heat for 15 minutes, take it out and cool it naturally to room temperature;

[0118] i) repeating steps (b)-(g) for the next round of antibody staining until all staining of one antibody group in the primary antibody is completed;

[0119] j) Nuclear staining (DAPI)

[0120] Add DAPI working solution, incubate at room temperature for 10 minutes, and rinse 3 times with 1× TBST buffer, 2 minutes each time;

[0121] k) Sealing

[0122] Discard the washing solution, rinse with 1× TBST buffer for 2 minutes, and then wash with sterile deionized water for 3 minutes. After the tissue is slightly dry, add water-soluble anti-fluorescence quenching mounting medium to seal the slice, and fix the coverslip with colorless nail polish.

[0123] Spectral images were collected using an imaging microscope, and the images were identified using case image analysis software. Various indicators were determined and each cell subpopulation was analyzed on the same tissue section.

[0124] V. Solution Exploration

[0125] Two schemes are set: panel 1 and panel 2.

[0126] In panel 1, the corresponding fluorescence channels of each antibody are as follows: CD8 antibody corresponds to the 570nm fluorescence channel, CD20 antibody corresponds to the 480nm fluorescence channel, CD23 antibody corresponds to the 620nm fluorescence channel, CD45 antibody corresponds to the 690nm fluorescence channel, PANCK antibody corresponds to the 780nm fluorescence channel, and PDL1 antibody corresponds to the 520nm fluorescence channel.

[0127] Finally, the dyeing rounds of this scheme are determined as follows:

[0128] Round 1: CD45

[0129] Round 2: CD8

[0130] Round 3: PD-L1

[0131] Round 4: CD20

[0132] Round 5: CD23

[0133] Sixth round Panck

[0134] Finally, DAPI.

[0135] The specific analysis scheme is shown in Table 2:

[0136] Table 2 Panel 1 Multiplex Immunohistochemistry Protocol

[0137]

[0138] In Panel 2, the corresponding fluorescence channels of each antibody are as follows: CD8 antibody corresponds to the 520nm fluorescence channel, CD20 antibody corresponds to the 620nm fluorescence channel, CD23 antibody corresponds to the 480nm fluorescence channel, CD45 antibody corresponds to the 690nm fluorescence channel, PANCK antibody corresponds to the 780nm fluorescence channel, and PDL1 antibody corresponds to the 570nm fluorescence channel.

[0139] Finally, the dyeing rounds of this scheme are determined as follows:

[0140] Round 1: CD45

[0141] Round 2: CD8

[0142] Round 3: PD-L1

[0143] Round 4: CD20

[0144] Round 5: CD23

[0145] Sixth round Pan ck

[0146] Finally, DAPI.

[0147] See Table 3 for the specific analysis scheme:

[0148] Table 3 Panel 2 multiplex immunohistochemistry protocol

[0149]

[0150]

[0151] Compare antibody-dye expression in different panels. See Figure 7 to Figure 12 ,After comprehensive evaluation of the results, the expression of each target in panel 1 is better than that in panel 2, so panel 1 can be screened out as the definite solution.

[0152] The above description is only a preferred embodiment of the present invention, and does not limit the implementation mode and protection scope of the present invention. For those skilled in the art, it should be aware that all solutions obtained by equivalent substitutions and obvious changes made using the contents of the specification and illustrations of the present invention should be included in the protection scope of the present invention.

Claims

1. A multiplex fluorescent immunohistochemistry kit for evaluating the immune microenvironment of skin squamous cell carcinoma, characterized in that: Includes a monoclonal antibody panel as primary antibody and a fluorescent dye panel; The monoclonal antibody group includes CD8 monoclonal antibody, CD20 monoclonal antibody, CD23 monoclonal antibody, CD45 monoclonal antibody, PANCK monoclonal antibody and PDL1 monoclonal antibody; The fluorescent dye set includes six different fluorescent dyes, each corresponding to the monoclonal antibody.

2. The multiplex fluorescent immunohistochemistry kit for evaluating the immune microenvironment of skin squamous cell carcinoma according to claim 1, characterized in that: The fluorescent dye is TSA dye, including 570nm fluorescent dye, 480nm fluorescent dye, 620nm fluorescent dye, 690nm fluorescent dye, 780nm fluorescent dye, and 520nm fluorescent dye corresponding to CD8 monoclonal antibody, CD20 monoclonal antibody, CD23 monoclonal antibody, CD45 monoclonal antibody, PANCK monoclonal antibody, and PDL1 monoclonal antibody, respectively.

3. The multiplex fluorescent immunohistochemistry kit for evaluating the immune microenvironment of skin squamous cell carcinoma according to claim 2, characterized in that: The fluorescent dye set also includes a signal amplification solution.

4. The multiplex fluorescent immunohistochemistry kit for evaluating the immune microenvironment of skin squamous cell carcinoma according to claim 1, characterized in that: The preparation method of the primary antibody working solution is as follows: CD8 is diluted at 1:200, CD20 is diluted at 1:400, CD23 is diluted at 1:1000, CD45 is diluted at 1:600, PD-L1 is diluted at 1:500, and PANCK is diluted at 1:1000 to prepare a combined primary antibody working solution.

5. The multiplex fluorescent immunohistochemistry kit for evaluating the microenvironment of skin squamous cell carcinoma according to claim 1, characterized in that: It also includes antigen retrieval solution, non-specific protein blocking agent, secondary antibody, antibody diluent, buffer, nuclear stain, mounting medium, dewaxing agent, and hydrating agent.

6. The multiplex fluorescent immunohistochemistry kit for evaluating the microenvironment of skin squamous cell carcinoma according to claim 5, characterized in that: The antigen repair solution is Tris-EDTA antigen repair solution, pH9.0, the dilution ratio of the Tris-EDTA antigen repair solution, pH9.0 stock solution is 1:50, and the pH is 9.0; the non-specific protein blocking agent includes bovine serum albumin; the secondary antibody is a secondary antigen solution matched with TSA dye; the buffer is 1×TBST buffer; the nuclear stain is a DAPI stock solution diluted with deionized water; the mounting medium is a water-soluble anti-fluorescence quenching mounting medium; the dewaxing agent includes xylene; the hydrating agent includes ethanol with gradient concentrations of 100%, 95%, and 75% by volume.

7. A skin squamous cell carcinoma microenvironment assessment system, characterized in that: It comprises a multiplex fluorescent immunohistochemistry kit as described in any one of claims 1 to 6 and a pathological image acquisition and analysis system adapted thereto; a pathological picture is obtained by performing multiplex fluorescent immunohistochemistry operations on a biological sample; the pathological image acquisition and analysis system acquires an image of the pathological picture and analyzes the image based on the following markers: CD8, CD20, CD23, CD45, PANCK and PDL1.

8. The skin squamous cell carcinoma microenvironment assessment system according to claim 7, characterized in that: When performing immunohistochemistry, after the specimen is dewaxed and hydrated, the antigen retrieval and staining rounds of each antibody in the primary monoclonal antibody group are as follows: In the first round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with CD45 primary antibody for 60 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 690 nm, rinsing with TBST 3 times for 3 min each; In the second round, Tris-EDTA antigen retrieval solution, pH 9.0, was used for primary antigen retrieval, the retrieval time was 15 min, blocking was performed for 10 min, CD8 primary antibody was incubated for 60 min, TBST was rinsed 3 times for 3 min each, HRP secondary antibody was incubated for 10 min, TBST was rinsed 3 times for 3 min each, TSA staining was performed at 570 nm, and TBST was rinsed 3 times for 3 min each; In the third round, antigen retrieval was performed once with Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with PDL1 primary antibody for 30 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 520 nm, rinsing with TBST 3 times for 3 min each; In the fourth round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with CD20 primary antibody for 30 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 480 nm, rinsing with TBST 3 times for 3 min each; In the fifth round, antigen retrieval was performed using Tris-EDTA antigen retrieval solution, pH 9.0, with a retrieval time of 15 min, blocking for 10 min, incubation with CD23 primary antibody for 60 min, rinsing with TBST 3 times for 3 min each, incubation with HRP secondary antibody for 10 min, rinsing with TBST 3 times for 3 min each, TSA staining at 620 nm, rinsing with TBST 3 times for 3 min each; In the sixth round, Tris-EDTA antigen retrieval solution, pH 9.0, was used for antigen retrieval for 15 min, blocked for 10 min, incubated with PANCK primary antibody for 60 min, rinsed with TBST 3 times for 3 min each, incubated with HRP secondary antibody for 10 min, rinsed with TBST 3 times for 3 min each, stained with TSA at 780 nm, and rinsed with TBST 3 times for 3 min each.

9. The skin squamous cell carcinoma immune microenvironment assessment system according to claim 8, characterized in that: The preparation method of TSA dye is as follows: dilute the fluorescent dye mother solution in 100ul signal amplification solution at a ratio of 1:100 and prepare it before use.

10. The skin squamous cell carcinoma immune microenvironment assessment system according to claim 7, characterized in that: The biological sample is skin squamous cell carcinoma tissue.